Rectal Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer – Drugs In Development, 2021, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 19, 15, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AD Pharmaceuticals Co Ltd

Advaxis Inc

Alkermes Plc

Amphivena Therapeutics Inc

Apexigen Inc

AptaBio Therapeutics Inc

AstraZeneca Plc

Beijing Konruns Pharmaceutical Co Ltd

BioAtla Inc

Bristol-Myers Squibb Co

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Diverse Biotech Inc

Eisai Co Ltd

Eli Lilly and Co

Ellipses Pharma Ltd

GlaxoSmithKline Plc

Incyte Corp

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

LipoMedix Pharmaceutical Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Novartis AG

Oncolys BioPharma Inc

OncXerna Therapeutics Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Pieris Pharmaceuticals Inc

Precigen Inc

Sanofi

Shanghai Haihe Biopharma Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

SQZ Biotechnologies Co

Stcube Inc

Taiho Oncology Inc

Teon Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Rectal Cancer - Overview

Rectal Cancer - Therapeutics Development

Rectal Cancer - Therapeutics Assessment

Rectal Cancer - Companies Involved in Therapeutics Development

Rectal Cancer - Drug Profiles

Rectal Cancer - Dormant Projects

Rectal Cancer - Discontinued Products

Rectal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Rectal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Rectal Cancer – Pipeline by AD Pharmaceuticals Co Ltd, 2021

Rectal Cancer – Pipeline by Advaxis Inc, 2021

Rectal Cancer – Pipeline by Alkermes Plc, 2021

Rectal Cancer – Pipeline by Amphivena Therapeutics Inc, 2021

Rectal Cancer – Pipeline by Apexigen Inc, 2021

Rectal Cancer – Pipeline by AptaBio Therapeutics Inc, 2021

Rectal Cancer – Pipeline by AstraZeneca Plc, 2021

Rectal Cancer – Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2021

Rectal Cancer – Pipeline by BioAtla Inc, 2021

Rectal Cancer – Pipeline by Bristol-Myers Squibb Co, 2021

Rectal Cancer – Pipeline by CytomX Therapeutics Inc, 2021

Rectal Cancer – Pipeline by Daiichi Sankyo Co Ltd, 2021

Rectal Cancer – Pipeline by Diverse Biotech Inc, 2021

Rectal Cancer – Pipeline by Eisai Co Ltd, 2021

Rectal Cancer – Pipeline by Eli Lilly and Co, 2021

Rectal Cancer – Pipeline by Ellipses Pharma Ltd, 2021

Rectal Cancer – Pipeline by GlaxoSmithKline Plc, 2021

Rectal Cancer – Pipeline by Incyte Corp, 2021

Rectal Cancer – Pipeline by Innovent Biologics Inc, 2021

Rectal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Rectal Cancer – Pipeline by LipoMedix Pharmaceutical Inc, 2021

Rectal Cancer – Pipeline by Merck & Co Inc, 2021

Rectal Cancer – Pipeline by Merck KGaA, 2021

Rectal Cancer – Pipeline by Millennium Pharmaceuticals Inc, 2021

Rectal Cancer – Pipeline by Novartis AG, 2021

Rectal Cancer – Pipeline by Oncolys BioPharma Inc, 2021

Rectal Cancer – Pipeline by OncXerna Therapeutics Inc, 2021

Rectal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Rectal Cancer – Pipeline by PDS Biotechnology Corp, 2021

Rectal Cancer – Pipeline by Pieris Pharmaceuticals Inc, 2021

Rectal Cancer – Pipeline by Precigen Inc, 2021

Rectal Cancer – Pipeline by Sanofi, 2021

Rectal Cancer – Pipeline by Shanghai Haihe Biopharma Co Ltd, 2021

Rectal Cancer – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Rectal Cancer – Pipeline by SQZ Biotechnologies Co, 2021

Rectal Cancer – Pipeline by Stcube Inc, 2021

Rectal Cancer – Pipeline by Taiho Oncology Inc, 2021

Rectal Cancer – Pipeline by Teon Therapeutics Inc, 2021

Rectal Cancer – Dormant Projects, 2021

Rectal Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Rectal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports